The generic version of Boniva is expected to be released after 06 May, 2023, following the expiration of its last patent.
Boniva is used for the treatment and prevention of osteoporosis in postmenopausal women. It does this through the once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid.
Boniva has a total of 3 drug patents, all of which have expired. The last patent of Boniva was US7410957, titled 'Method of treatment using bisphosphonic acid', which expires on 2023-05-06. Boniva generic will be available shortly after. Below are the details of the patent: